Prosecution Insights
Last updated: April 19, 2026
Application No. 17/246,044

PROTEIN POLYURETHANE ALLOYS AND LAYERED MATERIALS INCLUDING THE SAME

Non-Final OA §102§103§DP
Filed
Apr 30, 2021
Examiner
KOROTCHKINA, LIOUBOV G
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Modern Meadow Inc.
OA Round
4 (Non-Final)
29%
Grant Probability
At Risk
4-5
OA Rounds
3y 7m
To Grant
88%
With Interview

Examiner Intelligence

Grants only 29% of cases
29%
Career Allow Rate
12 granted / 41 resolved
-30.7% vs TC avg
Strong +59% interview lift
Without
With
+59.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
63 currently pending
Career history
104
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
45.1%
+5.1% vs TC avg
§102
10.8%
-29.2% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 41 resolved cases

Office Action

§102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/24/2025 has been entered. Priority This application claims benefit of provisional applications 63/110,760 filed 11/06/2020 and 63/018,891 filed 05/01/2020. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Information Disclosure Statement The information disclosure statements (IDS) submitted on 10/24/2025 and 01/14/2026 comply with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Status of the Claims Claims 30-34 and 36-45 are pending (claim set filed 03/18/2024) and are examined on the merits herein. Withdrawal of Rejections The response, Declaration under 37 C.F.R. 1.132 by Dale Handlin and Appendix to Specification filed on 10/24/2025 are acknowledged. All of the response, Declaration and arguments have been thoroughly reviewed and considered. For the purposes of clarity of the record, the reasons for the Examiner's withdrawal and/or maintaining if applicable, of the substantive or essential claim rejections are detailed directly below and/or in the Examiner's response to arguments section. The previous claims 30-34, 36-40, 44 and 45 rejection under 35 U.S.C. 102(a)(1) has been withdrawn necessitated by Applicant’s arguments. The previous claims 41-43 rejection under 35 U.S.C. 103 has been withdrawn necessitated by Applicant’s arguments. The previous claims 30, 39 and 44 double patenting rejection has been withdrawn. New Rejections Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. First Rejection Claims 30-34 and 36-45 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Li (Li et al. RSC Adv., 2016, 6, 12837-12849 on record in IDS). Regarding claim 30, Li teaches soy protein polyurethane composite films which are fabricated by the process of blending waterborne polyurethane (WPU) and soy protein isolate (SPI), casting and evaporation (Abstract). Li describes that WPU is synthesized prior to blending with SPI. SPI is stirred in water to obtain slurry with pH adjusted to 10.0. Then SPI slurry is added to 10 wt% WPU aqueous dispersion and stirred at room temperature. After centrifuge degassing, the homogeneous composite solution is poured into PTFE board to evaporate and to obtain an even composite film (p. 12838, right column, last paragraph). The scheme of synthesis of composite soy protein-WPU film is presented on Scheme 2 (p. 12840). The structure, thermal and mechanical properties of the composite films were analyzed by Li and it was concluded that SPI showed good miscibility with castor oil-based WPU due to intermolecular interactions between WPU and SPI and that SPI increased hydrophilicity, thermal stability and tensile strength of the composite films (p. 12847, left column, last paragraph and right column, 1st paragraph). Claim 30 is interpreted as directed to the structure of a soy protein dissolved within a polyurethane. Although the limitation “dissolved within a polyurethane” is product-by-process limitation MPEP 2113, in the interest of compact prosecution, the prior art has been applied to take into consideration the process step since Applicant’s arguments state that the claimed process step of dissolving the soy protein within the polyurethane provides the claimed properties. Therefore, since the prior art teaches not only the structure claimed but the product by process step claimed, it is the Examiner’s position the prior art meets the claimed properties. Note MPEP 2113 " Once the examiner provides a rationale tending to show that the claimed product appears to be the same or similar to that of the prior art, although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an nonobvious difference between the claimed product and the prior art product. “ Further, pursuant to MPEP 2112.01(II), “Products of identical chemical composition cannot have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present.” Thus, since Li teaches mixing the instant structural components, i.e. soy protein and polyurethane, and mentions good miscibility of soy protein within the polyurethane indicating that soy protein is dissolved within the polyurethane, the structure of Li teaching will inherently possess the properties of the claimed structure. Therefore, claim 30 is anticipated by Li teaching. Claims 31-34, 36-38 and 41-43 are directed to different properties of the structure of claim 30 and do not contain limitations altering the structure. Therefore claims 31-34, 36-38 and 41-43 are anticipated by Li. Regarding claims 39 and 40, Li teaches preparation of a series of SPI-WPU composite films with 10-90 wt% soy protein and 10-90 wt% WPU (p. 12840, Table 1). Thus, Li teaching anticipates claims 39 and 40. It is further pointed out that since the prior art teaches the same amount of the soy protein and polyurethane and the same process step of dissolving the soy protein within the polyurethane, the prior art must have the same properties as claimed. Regarding claim 44, Li teaches soy protein isolate (SPI) (p. 12838, right column, 2nd paragraph). Thus, Li teaching anticipates claim 44. Regarding claim 45, Li teaches treatment of SPI with NaOH at pH 10.0 that can chemically modify soy protein. Besides, Li discloses that soy protein forms hydrogen bonds with WPU indicating soy protein modification (p. 12842, left column, 1st paragraph). Thus, Li teaching anticipates claim 45. Second Rejection Claims 30-34 and 36-44 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Madbouly (Madbouly and Lendlein Macromol. Mater. Eng., 2012, 297, 1213-1224 on record in IDS). Regarding claim 30, Madbouly teaches synthesis of degradable polyurethane/soy protein polymer blends (Abstract). Madbouly describes that polyurethane (PU) is synthesized prior to blending with soy protein (SP). SP formulation is dispersed in water and then mixed with PU dispersion at room temperature with vigorous stirring for 1h. The blend solutions are cast into petri-dishes and dried (p. 1215, left column, 2nd paragraph). The obtained samples were optically clear. Their structure and thermal properties indicated SP and PU miscibility over the entire composite range (p. 1217, left column, 2nd and 3rd paragraphs). Additionally, the miscibility over the entire range of concentrations was confirmed by decrease in melting point and melting enthalpy with increasing SP content (p. 1218, right column, 1st paragraph). Claim 30 is interpreted as directed to the structure of a soy protein dissolved within a polyurethane. Although the limitation “dissolved within a polyurethane” is product-by-process limitation MPEP 2113, in the interest of compact prosecution, the prior art has been applied to take into consideration the process step since Applicant’s arguments state that the claimed process step of dissolving the soy protein within the polyurethane provides the claimed properties. Therefore, since the prior art teaches not only the structure claimed but the product by process step claimed, it is the Examiner’s position the prior art meets the claimed properties. Note MPEP 2113 " Once the examiner provides a rationale tending to show that the claimed product appears to be the same or similar to that of the prior art, although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an nonobvious difference between the claimed product and the prior art product. “ Further, pursuant to MPEP 2112.01(II), “Products of identical chemical composition cannot have mutually exclusive properties.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present.” Since Madbouly teaches mixing the instant structural components, i.e. soy protein and polyurethane, and mentions good miscibility of soy protein within the polyurethane over the entire range of concentrations that indicates that soy protein is dissolved within the polyurethane. Therefore, the structure of Madbouly teaching will inherently have the properties of the claimed structure. Thus, claim 30 is anticipated by Madbouly. Claims 31-34, 36-38 and 41-43 are directed to different properties of the structure of claim 30 and do not contain limitations altering the structure. Therefore claims 31-34, 36-38 and 41-43 are anticipated by Madbouly. Regarding claims 39 and 40, Madbouly teaches preparation of SPI-PU blends with 10-60 wt% soy protein and 40-90 wt% WPU (p. 1217, left column, 2nd paragraph). Thus, Madbouly teaching anticipates claims 39 and 40. It is further pointed out that since the prior art teaches the same amount of the soy protein and polyurethane and the same process step of dissolving the soy protein within the polyurethane, the prior art must have the same properties as claimed. Regarding claim 44, Madbouly teaches soy protein isolate (SPI) (p. 1214, right column, 3rd paragraph). Thus, Madbouly teaching anticipates claim 44. Response to Arguments Applicant’s arguments, filed 10/24/2025 and Declaration under 37 C.F.R. 1.132 by Dale Handlin, with respect to prior art of Liu have been fully considered and are persuasive. The previous claims 30-34, 36-40, 44 and 45 rejection under 35 U.S.C. 102(a)(1) and claims 41-43 rejection under 35 U.S.C. 103 have been withdrawn. Upon further consideration new rejections are applied as described above. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LIOUBOV G KOROTCHKINA whose telephone number is (571)270-0911. The examiner can normally be reached Monday-Friday: 8:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila G Landau can be reached at (571)272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.G.K./Examiner, Art Unit 1653 /SHARMILA G LANDAU/Supervisory Patent Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Apr 30, 2021
Application Filed
Dec 12, 2023
Non-Final Rejection — §102, §103, §DP
Mar 18, 2024
Response Filed
Apr 19, 2024
Final Rejection — §102, §103, §DP
Jul 25, 2024
Request for Continued Examination
Jul 30, 2024
Response after Non-Final Action
Sep 24, 2024
Non-Final Rejection — §102, §103, §DP
Dec 18, 2024
Examiner Interview Summary
Mar 26, 2025
Notice of Allowance
Oct 24, 2025
Request for Continued Examination
Oct 27, 2025
Response after Non-Final Action
Feb 25, 2026
Non-Final Rejection — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12577552
FACTOR IX VARIANTS AND USES THEREOF IN THERAPY
2y 5m to grant Granted Mar 17, 2026
Patent 12461092
SCREENING METHOD FOR APP CLEAVAGE ACTIVITY-CONTROLLING SUBSTANCES OF ADAMTS4
2y 5m to grant Granted Nov 04, 2025
Patent 12428663
IDENTIFICATION OF DNA POLYMERASE THETA INACTIVATION MECHANISM
2y 5m to grant Granted Sep 30, 2025
Patent 12385078
BIOELECTRICAL SENSOR DEVICE
2y 5m to grant Granted Aug 12, 2025
Patent 12385027
Polypeptides Having Xylanase Activity And Polynucleotides Encoding Same
2y 5m to grant Granted Aug 12, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

4-5
Expected OA Rounds
29%
Grant Probability
88%
With Interview (+59.0%)
3y 7m
Median Time to Grant
High
PTA Risk
Based on 41 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month